Fig. 3: Pie charts demonstrating the reasons for sorafenib discontinuation.
From: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Reasons for discontinuation are demonstrated in patients aged ≥75 years (left) and aged <75 years (right) according to death, disease progression, toxicity or other.
